# DESCRIPTION

## BACKGROUND

- introduce immune system and neuroactive molecules
- describe GABA and its role in central nervous system
- discuss GABA receptors and their types
- explain GABA's effect on immune system
- describe autoimmune diseases and graft rejection
- highlight need for immune response modulation

## SUMMARY

- summarize GABA's effects on autoimmune responses
- introduce GABA receptor activating ligands and PAMS

## Embodiment 1

- outline method for reducing inflammatory immune response

## Embodiment 2

- specify PAM's effect on inflammatory immune response

## Embodiment 3

- detail inflammatory immune response comprising T cell proliferation

## Embodiment 4

- describe PAM's promotion of regulatory immune response

## Embodiment 5

- specify regulatory immune response

### Embodiment 6

- specify reduction in inflammatory immune response

### Embodiment 7

- specify downregulation of cytokines or chemokines

### Embodiment 8

- specify downregulation of IL-1

### Embodiment 9

- specify downregulation of IL-12

### Embodiment 10

- specify downregulation of IL-6

### Embodiment 11

- specify downregulation of TNF

### Embodiment 12

- specify downregulation of IFN-Î³

### Embodiment 13

- specify downregulation of GMCSF and IL-23

### Embodiment 14

- specify downregulation of IL-23

### Embodiment 15

- specify reduction of inflammation-related T-cell types

### Embodiment 16

- specify reduction of CD8+ T cells

### Embodiment 17

- specify reduction of Th17 cells

### Embodiment 18

- specify increase in regulatory T cells

### Embodiment 19

- administer PAM with GABA receptor activating ligand

### Embodiment 20

- specify synergy of PAM and GABA receptor activating ligand

### Embodiment 21

- specify fold increase in effectiveness

### Embodiment 22

- specify lower dosage of GABA receptor activating ligand and/or PAM

### Embodiment 23

- specify percentage reduction in dosage of GABA receptor activating ligand

### Embodiment 24

- specify percentage reduction in dosage of PAM

### Embodiment 25

- specify subtherapeutic dosage of PAM

### Embodiment 26

- specify human subject

### Embodiment 27

- specify human subject with type I diabetes

### Embodiment 28

- specify human subject who is pre-diabetic

### Embodiment 29

- specify non-human mammal

### Embodiment 30

- specify synergistic effect of PAM and GABA receptor activating ligand

### Embodiment 31

- specify PAM type

### Embodiment 32

- specify barbiturate PAM

### Embodiment 33

- specify specific barbiturate PAMs

### Embodiment 34

- specify benzodiazepine PAM

### Embodiment 35

- specify specific benzodiazepine PAMs

### Embodiment 36

- specify alprazolam PAM

### Embodiment 37

- specify lower dosage of alprazolam

### Embodiment 38

- specify specific dosage of alprazolam

### Embodiment 39

- specify midazolam PAM

### Embodiment 40

- specify lower dosage of midazolam

### Embodiment 41

- specify specific dosage of midazolam

### Embodiment 42

- specify clonazepam PAM

### Embodiment 43

- specify lower dosage of clonazepam

### Embodiment 44

- specify specific dosage of clonazepam

### Embodiment 45

- specify neurosteroid PAM

### Embodiment 46

- specify specific neurosteroid PAMs

### Embodiment 47

- specify Algiax PAM

### Embodiment 48

- specify AP325 PAM

### Embodiment 49

- specify lower dosage of AP325

### Embodiment 50

- specify GABA as GABA receptor activating ligand

### Embodiment 51

- specify other GABA receptor activating ligands

### Embodiment 52

- exclude alcohol as GABA receptor activating ligand

### Embodiment 53

- exclude kavalactone as GABA receptor activating ligand

### Embodiment 54

- exclude skullcap or skullcap constituent as GABA receptor activating ligand

### Embodiment 55

- exclude valerian or valerian constituent as GABA receptor activating ligand

### Embodiment 56

- exclude volatile gas as GABA receptor activating ligand

### Embodiment 57

- specify treatment of inflammatory disease

### Embodiment 58

- specify specific inflammatory diseases

### Embodiment 59

- specify prevention of graft rejection

### Embodiment 60

- specify reduction of allergic response

### Embodiment 61

- specify specific allergic responses

### Embodiment 62

- exclude treatment of specific conditions

### Embodiment 63

- exclude administration of PAM for anesthesia or sedation

### Embodiment 64

- specify administration of BBB-permeable PAMs at low doses

### Definitions

- define GABA receptor activating ligand
- define positive allosteric modulator of GABAA receptor
- define subtherapeutic dosage
- define "in conjunction with" or "in combination with"
- define regulatory response

### DETAILED DESCRIPTION

- introduce PAMs and their effect on immune response
- describe synergistic effect of PAMs with GABA receptor activating ligands
- provide method of reducing inflammatory immune response and/or promoting regulatory immune response
- describe administration of PAM with GABA receptor activating ligand
- provide use of PAM for preparing medicament
- describe benefits of combination treatment
- provide methods of reducing inflammatory immune response and/or promoting regulatory immune response
- describe administration of PAM and GABA receptor activating ligand at lower dosages
- provide pharmaceutical formulations comprising PAM and GABA receptor activating ligand
- describe kits for practicing methods
- introduce uses of PAMs, optionally in combination with GABA receptor activating ligands
- describe treatment of diseases involving immune function
- describe peripheral administration of compounds
- describe reduction of inflammation and enhancement of Treg responses
- provide examples of inflammatory cytokines and chemokines
- describe treatment of inflammatory diseases
- describe use of PAMs in graft rejection
- describe use of PAMs in allergy and Th1 cell-mediated immune responses

### GABAA Receptor Positive Allosteric Modulators (PAMs)

- introduce PAMs of GABAA receptors
- provide examples of PAMs
- describe exclusion of certain PAMs
- provide examples of barbiturates
- provide examples of benzodiazepines
- provide examples of neurosteroids

### GABA Receptor Activating Ligands

- introduce GABA receptor activating ligands
- provide examples of GABA receptor activating ligands

### Combined Formulations

- introduce combined formulations of PAM(s) and GABA receptor activating ligand(s)
- describe GABA receptor activating ligand(s) used in combined formulations
- list examples of PAM(s) used in combined formulations
- exclude certain PAM(s) from combined formulations
- describe GABA receptor ligand(s) used in combined formulations
- provide example of combined formulation comprising GABA and alprazolam
- introduce preparation of salts, esters, amides, prodrugs, and derivatives
- describe preparation of salts using acid and base
- list examples of pharmaceutically acceptable salts
- describe preparation of esters
- describe preparation of amides
- describe preparation of prodrugs
- describe preparation of derivatives
- introduce administration routes for combined formulations
- describe parenteral administration
- describe topical administration
- describe oral administration
- describe nasal administration
- describe rectal administration
- describe local administration
- introduce pharmaceutically acceptable carriers
- describe carbohydrates as carriers
- describe antioxidants as carriers
- describe chelating agents as carriers
- describe low molecular weight proteins as carriers
- describe lipids as carriers
- describe compositions that reduce clearance or hydrolysis
- describe excipients or other stabilizers and/or buffers
- introduce manufacturing of oral dosage forms
- describe addition of excipients, disintegrators, binders, and lubricants
- describe compression and coating of tablets
- describe coating materials
- introduce other physiologically acceptable compounds
- describe wetting agents
- describe emulsifying agents
- describe dispersing agents
- describe preservatives
- introduce sterilization techniques
- describe unit dosage forms
- describe powders, tablets, pills, capsules, lozenges, suppositories, patches, nasal sprays, injectibles, implantable sustained
- describe pharmaceutical compositions for oral administration
- describe pharmaceutical compositions for inhalation
- describe pharmaceutical compositions for systemic administration
- describe depot preparations
- describe transdermal delivery systems

### Kits

- provide kits for practicing methods
- include GABA activating ligand and PAM containers
- optionally include labeling and instructional materials
- describe kit components and formulations

### EXAMPLES

- introduce use of PAM with GABA receptor activating ligand
- explain PAM function and synergy with GABA
- describe potential benefits of combination treatment
- outline method for testing T cell recall responses
- show effect of GABA alone on T cell proliferation
- show effect of alprazolam alone on T cell proliferation
- show effect of GABA and alprazolam combination on T cell proliferation
- discuss results and implications for treatment
- generalize findings to other GABA-R PAMs

